Actelion (ATLN.VX) has nominated GlaxoSmithKline's former boss and a second industry veteran to join the board at its May 5 annual meeting as it resists calls from hedge fund Elliott Advisors to consider selling up. Elliott said the move did not get to the root of Actelion's problems. The Swiss biotech group has come under fire from Elliott, its largest shareholder, for eroding shareholder value and the New York-based fund has urged Actelion to consider putting itself up for sale after a spate of product setbacks last year.
Source
